Journey Medical Corp (DERM) - Total Assets
Based on the latest financial reports, Journey Medical Corp (DERM) holds total assets worth $94.59 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Journey Medical Corp debt service capacity to assess how comfortably operating cash covers total debt obligations.
Journey Medical Corp - Total Assets Trend (2014–2025)
This chart illustrates how Journey Medical Corp's total assets have evolved over time, based on quarterly financial data. See net assets of Journey Medical Corp for net asset value and shareholders' equity analysis.
Journey Medical Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Journey Medical Corp's total assets of $94.59 Million consist of 70.7% current assets and 29.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 25.5% |
| Accounts Receivable | $29.78 Million | 31.5% |
| Inventory | $9.62 Million | 10.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $27.61 Million | 29.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Journey Medical Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see DERM market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Journey Medical Corp's current assets represent 70.7% of total assets in 2025, an increase from 59.2% in 2014.
- Cash Position: Cash and equivalents constituted 25.5% of total assets in 2025, down from 31.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 29.0% of total assets, an increase from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 31.5% of total assets.
Journey Medical Corp Competitors by Total Assets
Key competitors of Journey Medical Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Journey Medical Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.37 | 1.26 |
| Quick Ratio | 1.53 | 0.96 | 1.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.43 Million | $13.00 Million | $7.18 Million |
Journey Medical Corp - Advanced Valuation Insights
This section examines the relationship between Journey Medical Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.35 |
| Latest Market Cap to Assets Ratio | 1.44 |
| Asset Growth Rate (YoY) | 17.9% |
| Total Assets | $94.59 Million |
| Market Capitalization | $135.98 Million USD |
Valuation Analysis
Above Book Valuation: The market values Journey Medical Corp's assets above their book value (1.44x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Journey Medical Corp's assets grew by 17.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Journey Medical Corp (2014–2025)
The table below shows the annual total assets of Journey Medical Corp from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $94.59 Million | +17.88% |
| 2024-12-31 | $80.24 Million | +4.41% |
| 2023-12-31 | $76.85 Million | -26.92% |
| 2022-12-31 | $105.16 Million | +8.10% |
| 2021-12-31 | $97.28 Million | +87.42% |
| 2020-12-31 | $51.91 Million | +53.30% |
| 2019-12-31 | $33.86 Million | -90.17% |
| 2018-12-31 | $344.32 Million | -38.60% |
| 2017-12-31 | $560.79 Million | +79.40% |
| 2016-12-31 | $312.60 Million | +40.85% |
| 2015-12-31 | $221.93 Million | +24.53% |
| 2014-12-31 | $178.22 Million | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more